Teysuno Evrópusambandið - íslenska - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafúri, gimeracil, oteracil - magaæxli - Æxlishemjandi lyf - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Cloxacillin Vital Pharma Nordic Stungulyfs-/innrennslisstofn, lausn 2 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cloxacillin vital pharma nordic stungulyfs-/innrennslisstofn, lausn 2 g

vital pharma nordic aps - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 2 g

Imvanex Evrópusambandið - íslenska - EMA (European Medicines Agency)

imvanex

bavarian nordic a/s - breytt bóluefni ankara - bavarian nordic (mva-bn) veira - smallpox vaccine; monkeypox virus - Önnur veiru bóluefni, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 og 5. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Nordimet Evrópusambandið - íslenska - EMA (European Medicines Agency)

nordimet

nordic group b.v. - stendur - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - Æxlishemjandi lyf - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.

Gaviscon Mixtúra, dreifa Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

gaviscon mixtúra, dreifa

nordic drugs ab - calcii carbonas; aluminii hydroxidum; natrii hydrogenocarbonas; natrii alginas - mixtúra, dreifa

Gaviscon Tuggutafla Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

gaviscon tuggutafla

nordic drugs ab - aluminium hydroxide; sodium hydrogen carbonate; acidum alginicum - tuggutafla

Vaxchora Evrópusambandið - íslenska - EMA (European Medicines Agency)

vaxchora

bavarian nordic a/s - vibrio cholerae, álag cvd 103-hgr, lifandi - cholera - bóluefni - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. Þetta bóluefni ætti að vera notuð í samræmi við opinbera tillögur.

Penovet vet. Stungulyf, dreifa 300 .000 a.e./ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

penovet vet. stungulyf, dreifa 300 .000 a.e./ml

boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum - stungulyf, dreifa - 300 .000 a.e./ml

Selevitan, vet. Stungulyf, lausn Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

selevitan, vet. stungulyf, lausn

boehringer ingelheim animal health nordics a/s - natrii selenis; tocopherolum (alfa) acetat - stungulyf, lausn

Streptocillin vet. Stungulyf, dreifa Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

streptocillin vet. stungulyf, dreifa

boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum; dihydrostreptomycinum súlfat - stungulyf, dreifa